Clot-Buster Drug Gets DCGI Clearance For Human Trial

The Drug Controller General of India (DCGI) has cleared a bio-therapeutic clot-buster drug for phase-one human clinical trials, a statement said Friday.

The drug, earlier licensed from a US-based firm, has been designed by Chandigarh-based Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology (CSIR-IMTECH).

Quiz on Heart Attack
The risk factors that work behind the scene before a heart attack are familiar to many. But do you realize the extent to which your lifestyle choices are putting your life at risk? Can you identify a heart attack when it occurs? Take our quiz and find out.

"Clot-specific streptokinase (CSSK), a pioneering bio-therapeutic clot buster drug from the CSIR-IMTECH has been cleared Thursday by the office of the DCGI for Phase-One Human Clinical trials," the statement from CSIR said.

The drug is helpful in saving lives of patients suffering heart attacks; it can also reduce the risk of internal bleeding, associated with the use of clot busters.

The drug has recently been successfully tried in test animals including monkeys. Its design and process development and scale-up was achieved by a team led by CSIR-IMTECH Director Girish Sahni.

Source-IANS

Angioplasty - 3D
Interactive section of Medindia gives explanation for Angioplasty - 3D.

Top 11 Latest Facts & Figures on Heart Attacks
Heart attack usually occurs when a clot blocks the blood supply to the heart. If not treated, it can lead to death. Here are must know facts on heart attacks.